Trial Profile
A Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination with Cisplatin and Docetaxel in Patients with Advanced Non-squamous Non-Small Cell Lung Cancer (nsNSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Dec 2015 New trial record